DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Artículo científico (JournalArticle)
Cold plasma-treated medium preferentially eliminates doxorubicin-resistant osteosarcoma cells
Osteosarcoma (OS) is an aggressive bone cancer with poor prognosis, largely due to the limited effectiveness of current treatments such as doxorubicin (DX). Developing ways to overcome DX resistance is a significant clinical challenge. Here, we used two DX-resistant models to study the potential of Cold Plasma Treated Medium (PTM) to prevent DX resistance in OS. During the acquisition of the resistant phenotype upon long-term DX exposure, OS resistant cells became less proliferative, overexpressed the drug resistance-related efflux pump MDR1 and displayed a concomitant loss of SOD2 or GPX1. According to the reduced expression of these antioxidant enzymes, PTM treatment produced higher levels of oxidative express and was more effective in eradicating DX-resistant cells. Moreover, PTM reduced the expression of MDR1, thus sensitizing resistant cells to DX. These findings uncover new vulnerabilities of DX-resistant cells related with their inability to cope with excessive oxidative stress and their dependence on MDR1 that can be exploited using PTM-based treatments to provide new therapeutic approaches for the management of drug resistance in OS., This work was supported by the Agencia Estatal de Investigación (AEI) [MICINN/Fondo Europeo de Desarrollo Regional (FEDER) (grants PID2019-106666RB-I00 and PID2022-142020OB-I00 to R.R. and PID2019- 103892RB-I00/AEI/10.13039/501100011033 to C.C.) and ISC III/FEDER (Consorcio CIBERONC - CB16/12/00390]; the Plan de Ciencia Tecnología e Innovación del Principado de Asturias/FEDER [grant IDI/2021/000027 to R.R. and Severo Ochoa predoctoral fellowships BP‐ 20–046 to B.G. and BP-21–084 to DM]; Fundación Científca de la Asociación Española Contra el Cáncer (AECC) (predoctoral fellowship to CH); CC belongs to SGR2022-1368 and acknowledges Generalitat de Catalunya for the ICREA Academia Award for Excellence in Research., Peer reviewed